<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057975</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-545</org_study_id>
    <nct_id>NCT05057975</nct_id>
  </id_info>
  <brief_title>Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis</brief_title>
  <acronym>SUNSAS</acronym>
  <official_title>Validation d'Une Solution Digitale intégrée (SUNrise®) d'Analyse Automatique Des Mouvements Mandibulaires Par Intelligence Artificielle Versus Polysomnographie Pour le Diagnostic du Syndrome d'Apnées Obstructives du Sommeil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunrise</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICUREsearch</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunrise</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validation of an integrated digital solution (SUNrise®) of mandibular movement automatic&#xD;
      analysis by artificial intelligence versus polysomnography for obstructive sleep apnea&#xD;
      diagnosis: a prospective, randomized, parallel-arm, open-label, multicenter, national,&#xD;
      controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The new Sunrise integrated digital solution is a disposable 3 gram sensor that sits on the&#xD;
      chin for sleep disorders diagnosis. This device records mandibular movements, head movements&#xD;
      and position during sleep. Data acquisition is done through a mobile application installed on&#xD;
      the user smartphone. Data is then transferred automatically at the end of the test&#xD;
      (overnight) to a cloud platform where it is automatically analyzed. The Health Care&#xD;
      Professional (HCP) and the patient have access to sleep parameters and report.&#xD;
&#xD;
      The objective of this trial is to determine the place of the Sunrise device in the care&#xD;
      pathway in France for patients suspected of having OSA. The assumption is that Sunrise is&#xD;
      both non-inferior to the normal practice (i.e., the PSG) on sleepiness at 3 months&#xD;
      post-diagnosis, and superior to the PSG (outpatient or in-lab) in terms of time between&#xD;
      inclusion and diagnosis appointment and treatment initiation. By speeding up the treatment&#xD;
      initiation, the hypothesis is that Sunrise is also superior to the PSG on sleepiness as well&#xD;
      as quality of life and work productivity at 3 months post-inclusion. Another assumption is&#xD;
      that Sunrise is non-inferior to the PSG on CPAP compliance at 3 months following treatment&#xD;
      initiation.&#xD;
&#xD;
      The SUNSAS study will be launched in 14 centers (public and private) in France and will&#xD;
      include 848 patients aged 18 to 80 years. Eligible patients will be included and randomized&#xD;
      in 2 arms, i.e., the Sunrise arm and the PSG arm. An appointment to discuss the diagnosis and&#xD;
      treatment options (for patients suffering from OSA) will be arranged after the procedure (PSG&#xD;
      or Sunrise) is performed. On site follow-up visits will be then organized at 3 months&#xD;
      post-inclusion and at 3 months post-diagnosis, and a phone call will be scheduled at 3 months&#xD;
      post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, controlled, randomized, parrallel, open label, multicenter and national</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in daily sleepiness</measure>
    <time_frame>3 months post-diagnosis</time_frame>
    <description>To determine the non-inferiority of Sunrise vs PSG on sleepiness at 3 months post-diagnosis using the Epworth Sleepiness Scale (ESS) score.&#xD;
The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher the average sleep propensity in daily life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the superiority of Sunrise vs PSG in terms of time between inclusion and diagnosis appointment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to treatment</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>To determine the superiority of Sunrise vs PSG in terms of time between inclusion and treatment initiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily sleepiness</measure>
    <time_frame>3 months post inclusion</time_frame>
    <description>To determine the superiority of Sunrise vs PSG on sleepiness at 3 months post-inclusion using ESS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 months post inclusion visit</time_frame>
    <description>To determine the superiority of Sunrise vs PSG on quality of life at 3 months post-inclusion using Short Form 36 (SF-36) SF-36 is a 0-100 scale score, a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 months post inclusion visit</time_frame>
    <description>To determine the superiority of Sunrise vs PSG on quality of life at 3 months post-inclusion using Quebec Sleep Questionnaire (QSQ).&#xD;
QSQ utilizes 32 items to measure 5 domains: daytime sleepiness, diurnal symptoms, nocturnal symptoms, emotions, and social interactions.Item scores range from 1 to 7. Mean scores for each domain are calculated, and a total score is derived by calculating the mean of all items. Higher scores are associated with better better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in work productivity</measure>
    <time_frame>3 months post-inclusion</time_frame>
    <description>To determine the superiority of Sunrise vs PSG on work productivity at 3 months post-inclusion using WPAI:SHP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost (€)/QALY</measure>
    <time_frame>3 months post-diagnosis</time_frame>
    <description>cost (€)/QALY gained 3 months post-diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net profit for the French social security</measure>
    <time_frame>estimated at 3 years</time_frame>
    <description>Estimation of the net profit for the French social security at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of CPAP compliance data</measure>
    <time_frame>3 month after treatment initiation</time_frame>
    <description>To determine the non-inferiority of Sunrise vs PSG on CPAP compliance measured at 3 months post-treatment by comparing CPAP average usage in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Sunrise versus PSG diagnosis</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To confirm the diagnosis performance of Sunrise compared to PSG by comparing the obstructive respiratory disturbance index (ORDI) in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the obstructive respiratory disturbance index (ORDI)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To measure the variability of the ORDI by comparing the 3 obstructive respiratory disturbance index (ORDI) measures provided by the Sunrise device (used 3 nights)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">848</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Sunrise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home Sleep Test, OSA diagnosis based on mandibular movements recording</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polysomnography, OSA diagnosis based on local scoring by center</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sunrise</intervention_name>
    <description>Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.</description>
    <arm_group_label>Sunrise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>polysomnography</intervention_name>
    <description>Reference protocol to diagnose OSA (in-lab or outpatient PSG)</description>
    <arm_group_label>PSG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Man or woman aged between 18 to 80 years old&#xD;
&#xD;
          -  Patient referred for a suspicion of OSA&#xD;
&#xD;
          -  Patient having a smartphone and internet connection at home and able to use a mobile&#xD;
             application&#xD;
&#xD;
          -  Patient affiliated to the social security system&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          -  Patient with a previous sleep test performed within 5 years of inclusion&#xD;
&#xD;
          -  Patient previously treated for OSA within 5 years of inclusion&#xD;
&#xD;
          -  Patient suffering from severe chronic obstructive or restrictive pulmonary disease&#xD;
             with or without oxygen at the discretion of the investigator&#xD;
&#xD;
          -  Patient refusing to shave his beard that could prevent him to wear the device on the&#xD;
             chin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis PEPIN, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis PEPIN, Pr</last_name>
    <phone>+33 4 76 76 87 66</phone>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric GAGNADOUX, Pr</last_name>
      <phone>+33 2 41 35 36 95</phone>
      <email>frgagnadoux@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Paris Seine Saint-Denis (HUPSSD, AP-HP),</name>
      <address>
        <city>Bobigny,</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carole PLANES, Pr</last_name>
      <phone>+33 1 48 95 56 37</phone>
      <email>carole.planes@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvelle clinique Bel-Air</name>
      <address>
        <city>Bordeaux</city>
        <zip>33073</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent PUEL, Dr</last_name>
      <phone>+33 5 57 81 05 87</phone>
      <email>vpuel001@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre PHILIP, Pr</last_name>
      <phone>+33 5 57 82 01 73</phone>
      <email>pierre.philip@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BOYER, dr</last_name>
      <phone>+33 1 49 81 26 77</phone>
      <email>laurent.boyer@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble Alpes,</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Louis PEPIN, Pr</last_name>
      <phone>+33 4 76 76 87 66</phone>
      <email>JPepin@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christelle CHARLEY MONACA, Pr</last_name>
      <phone>+33 3 20 44 63 62</phone>
      <email>Christelle.MONACA@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé la Louvière</name>
      <address>
        <city>Lille</city>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thibaut GENTINA, Dr</last_name>
      <phone>+33 3 20 55 02 50</phone>
      <email>docteur.gentina@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure PETER- DEREX, Dr</last_name>
      <phone>+33 4 72 07 17 69</phone>
      <email>laure.peter-derex@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Herve PEGLIASCO, dr</last_name>
      <phone>+33 4 13 42 72 40</phone>
      <email>H.PEGLIASCO@hopital-europeen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital Gui-de-Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves DAUVILLIERS, Pr</last_name>
      <phone>+33 4 67 33 63 61</phone>
      <email>y-dauvilliers@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Pia D'ORTHO, Pr</last_name>
      <phone>+33 1 40 25 84 01</phone>
      <email>marie-pia.dortho@bch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP CUP Hôpital Hôtel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien LÉGER, Pr</last_name>
      <phone>+33 1 42 34 85 63</phone>
      <email>damien.leger@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint-Laurent</name>
      <address>
        <city>Rennes</city>
        <zip>35700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud PRIGENT, dr</last_name>
      <phone>+33 2 99 25 65 35</phone>
      <email>dr.arnaudprigent@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polysomnography</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>home sleep test</keyword>
  <keyword>artificial intelligence</keyword>
  <keyword>mandibular movement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

